相关实验视频

Updated: Jan 13, 2026

Facilitating Drug Discovery: An Automated High-content Inflammation Assay in Zebrafish

Facilitating Drug Discovery: An Automated High-content Inflammation Assay in Zebrafish

Published on: July 16, 2012

设计,半合成和抗炎活性评估,用于缓解性结肠炎的烯化合物库

Cui-Fang Wang¹, Tian-Yi Zhou², Liu-Xia Lv²

¹Key Laboratory of Tropical Medicinal Resource Chemistry of Ministry of Education, College of Chemistry and Chemical Engineering, Hainan Normal University, Haikou, 571158, People's Republic of China; Key Laboratory of Marine Drugs, The Ministry of Education of China, School of Medicine and Pharmacy, Ocean University of China, Qingdao, 266003, People's Republic of China.

European journal of medicinal chemistry

|January 10, 2026

概括

一种新的烯衍生物c13显示出对性结肠炎 (UC) 有强大的抗炎作用. 这种有前途的天然化合物通过向关键炎症途径,有效治疗小鼠结肠炎.

科学领域:

自然产品化学自然产品化学
药理学药理学是指药理学的学科.
胃肠病学胃肠病学

背景情况:

性结肠炎 (UC) 是一种慢性炎症性肠病,影响生活质量和癌症风险.
海洋天然产品提供了新型抗炎支架的来源.
烯衍生物的治疗潜力正在被探索.

研究的目的:

识别和优化来自天然产品的新型抗炎药物,用于治疗性结肠炎.
为UC开发一种强效和安全的治疗候选药物.

主要方法:

对海洋自然产品库进行选,以确定生物活性支架.
合理设计和半合成101个烯衍生物.
在体外测试测量TNF-α,IL-6和IL-1β的抑制.
在DSS诱导的性结肠炎小鼠模型中的体内评估.
安全性概况的评估,包括最大耐受剂量 (MTD).

主要成果:

一种烯衍生物c13被确定为最佳的化合物.
c13表现出低IC50值的关键炎症性细胞因子 (TNF-α,IL-6,IL-1β) 的强烈抑制.
c13在DSS诱导的大肠炎的小鼠模型中显示出显著的治疗疗效.
c13表现出一个有利的安全概况,MTD>100 mg/kg.

结论:

天然烯衍生物c13是治疗性结肠炎的有希望的候选药物.
c13通过抑制炎症信号通路 (iNOS/COX-2) 和减少炎症媒介来缓解结肠炎.
进一步开发c13用于UC治疗是有必要的.

关键词:

它具有抗炎活性,具有抗炎活性.结构优化结构优化烯胺衍生物的衍生物性结肠炎是一种

更多相关视频

Author Spotlight: Advancing Therapeutics to Treat Vibriosis in Humans and Aquatic Organisms

Author Spotlight: Advancing Therapeutics to Treat Vibriosis in Humans and Aquatic Organisms

Published on: May 31, 2024

Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea

Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea

Published on: December 23, 2022

相关概念视频

Drugs for Treatment of Ulcerative Colitis in IBD

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Structure-Activity Relationships and Drug Design

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...

Peptic Ulcer Disease IV: Management

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...